AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

The "AI in Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for AI in biotechnology was valued at $3.8 billion in 2024. The market is ...

There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Over the last few years, artificial intelligence (AI) has reshaped the way we live and work, ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Developer tooling provider Anaconda Inc. today announced that it has closed a Series C funding round worth more than $150 million. Insight Partners led the investment with participation from Mubadala ...

The iShares Biotechnology ETF (NYSE: IBB) has risen for six straight months, notching its longest winning streak since 2012.

What’s the best way to bring your AI agent ideas to life: a sleek, no-code platform or the raw power of a programming language? It’s a question that sparks debate among developers, entrepreneurs, and ...